NANO Nanobiotix SA

Nanobiotix to Participate in Multiple Investor Conferences in February and March 2025

Nanobiotix to Participate in Multiple Investor Conferences in February and March 2025

PARIS and CAMBRIDGE, Mass., Jan. 29, 2025 (GLOBE NEWSWIRE) -- (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in fireside chats at following conferences:

Guggenheim SMID Cap Biotech Conference

Date: Thursday, February 6, 2025

Time: 1pm ET / 7pm CET

Location: New York, NY

Presenter: Bart van Rhijn, Chief Financial & Business Officer of Nanobiotix

Webcast link:

Leerink Global Healthcare Conference

Date: Wednesday, March 12, 2025

Time: 10:40pm ET / 4:40pm CET

Location: Miami, FL

Presenters: Laurent Levy, Chief Executive Officer of Nanobiotix and Bart van Rhijn, Chief Financial & Business Officer of Nanobiotix

Webcast link:

The fireside chats will be webcast live from the of the Investors section of the Company’s website. Replay of the webcast will be available following the event.

About NANOBIOTIX

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.

Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.

Nanobiotix is the owner of more than 25 patent families associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.

For more information about Nanobiotix, visit us at  or follow us on  and .

Contacts

Nanobiotix 
Communications Department

Brandon Owens

VP, Communications

+1 (617) 852-4835

Investor Relations Department

Craig West

SVP, Investor Relations

+1 (617) 583-0211

 
  
Media Relations 




France – HARDY

Caroline Hardy

50





  
Global – LifeSci Advisors

Kevin Gardner

+1 (617) 283-2856

 

 

Attachments



EN
29/01/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Nanobiotix SA

Damien Choplain ... (+2)
  • Damien Choplain
  • Khouloud Ben Aziza

Nanobiotix : Ongoing cancer care revolution

Nanobiotix is a late-stage biotech specialising in oncology. Its flagship project (NBTXR3) is the subject of a licence deal with Janssen that lends credibility to the clinical data already achieved and its commercial potential (ODDO BHF: peak sales >€ 5.8bn in the first three indications). It is expected to see solid newsflow with phase I results due in 2025 and interim phase III results in mid-2026e. The company has financial visibility out to Q4 2025e but this will, we think, require an additi...

Damien Choplain ... (+2)
  • Damien Choplain
  • Khouloud Ben Aziza

Nanobiotix : Révolution en cours dans la prise en charge des cancers

Nanobiotix est une biotech late-stage spécialisée en oncologie. Son actif phare (NBTXR3) a fait l’objet d’un deal de licence avec Janssen crédibilisant les données cliniques déjà produites ainsi que son potentiel commercial (ODDO BHF : peak sales > 5.8 Md€ dans les trois premières indications). La société devrait bénéficier d’un newsflow porteur avec des résultats de phase 1 attendus en 2025 et des résultats intermédiaires de phase 3 mi-2026e. La société dispose d’une visibilité financière jusqu...

 PRESS RELEASE

Nanobiotix to Participate in Multiple Investor Conferences in February...

Nanobiotix to Participate in Multiple Investor Conferences in February and March 2025 PARIS and CAMBRIDGE, Mass., Jan. 29, 2025 (GLOBE NEWSWIRE) -- (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in fireside chats at following conferences: Guggenheim SMID Cap Biotech Conference Date: Thursday, February 6, 2025Time: 1pm ET / 7pm CETLocation: New York, NYPresen...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch